ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer

This publication has 20 references indexed in Scilit:

• ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
  Annals of Oncology, 2006
• DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
  New England Journal of Medicine, 2006
• Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer
  Cancer, 2006
• A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
  Annals of Oncology, 2006
• Expression profiling of primary non-small cell lung cancer for target identification
  Oncogene, 2002
• ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells
  International Journal of Cancer, 2000
• Overexpression of glutathione S-transferase π enhances the adduct formation of cisplatin with glutathione in human cancer cells
  Free Radical Research, 1999
• Analysis of Incision Sites Produced by Human Cell Extracts and Purified Proteins during Nucleotide Excision Repair of a 1,3-Intrastrand d(GpTpG)-Cisplatin Adduct
  Journal of Biological Chemistry, 1996
• Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients
  European Journal Of Cancer, 1994
• Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
  Journal of Clinical Investigation, 1994